Quest Diagnostics (DGX) agreed to acquire select assets of Fresenius Medical Care's (FMS) Spectra Laboratories unit, which provides renal-specific laboratory testing services in the US, the companies said Monday.
Under a separate deal, Quest will provide laboratory services related to end-stage kidney disease and specialized water testing for patients and providers served by dialysis centers that Fresenius and its wholly owned and joint-venture partners operate in the US, according to a joint statement.
Financial terms weren't disclosed.
The acquisition is expected to close in H2, while the transition of services is anticipated to be completed by early 2026, the companies added.
Shares of Quest were up more than 4% and Fresenius was 0.7% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.